Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Posted on by Pencis

Dr. Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif, Fudan University, China

Dr. Mohammed Ahmed Akkaif is a Postdoctoral Researcher in the Department of Cardiology at Fudan University, China. He earned his Ph.D. in Clinical Pharmacy from Universiti Sains Malaysia in 2023, specializing in precision medicine, pharmacogenetics, and cardiology. A Young Ambassador for the European Association of Preventive Cardiology (2022–2024), he has published 34 peer-reviewed articles, with 29 indexed in SCI, and has over 2,179 citations. Recognized with the Young Researchers Award (ESC Asia 2022), he is a reviewer for 50+ high-impact journals. His research focuses on optimizing antithrombotic drug therapies through pharmacometabolomics for personalized cardiovascular treatment.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Mohammed Ahmed Akkaif began his academic journey with a strong foundation in Clinical Pharmacy at Universiti Sains Malaysia, where he completed his Doctor of Philosophy (PhD) in July 2023. During his PhD, he focused on the intersection of clinical pharmacy and biotechnology, gaining expertise in personalized and precision medicine. His academic accomplishments included publishing 10 articles (8 in SCI Q1 and Q2 journals) and presenting at six international conferences. This period also saw him design innovative approaches to enhance antithrombotic drug treatment, particularly through CYP2C19 genotype-guided antiplatelet therapy.

💼PROFESSIONAL ENDEAVORS:

Currently, Dr. Akkaif serves as a Postdoctoral Researcher in the Department of Cardiology at Fudan University’s Qingpu Branch of Zhongshan Hospital, China. His role involves leading advanced research in cardiovascular medicine, with a specialized focus on the clinical application of personalized medicine in cardiology. Additionally, he has served as a Young Ambassador for the European Association of Preventive Cardiology (EAPC) from 2022 to 2024, demonstrating his commitment to advancing heart health on a global scale. He has also contributed his expertise to several prestigious journals, with over 50 reviews in high-impact journals such as Journal of the American Heart Association and Arteriosclerosis, Thrombosis, and Vascular Biology.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR PHARMACOLOGY:

Dr. Akkaif’s research is primarily focused on pharmacogenetics and pharmacometabolomics, with a goal of improving personalized treatment strategies in cardiology. His work delves into the optimization of antithrombotic drug therapies through genetic and metabolic profiling, which holds the potential to revolutionize treatment protocols, making them more tailored to individual patient profiles. His research also bridges the gap between clinical pharmacy and biotechnology, aiming to develop more effective, individualized approaches to cardiovascular health.

🌍IMPACT AND INFLUENCE:

Dr. Akkaif’s contributions have already made a significant impact on both academic research and the practical application of precision medicine. He has been honored with the Young Researchers Award at the 2022 ESC Asia Conference in Singapore, highlighting his early recognition in the field. His research has also led to the publication of 34 peer-reviewed articles, with 29 of them indexed in SCI (Clarivate), reflecting his growing influence in the field of cardiovascular pharmacology. His work has contributed to advancing the understanding of genetic factors in drug response, and his findings are regularly cited by researchers and clinicians alike.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Akkaif’s publications have earned him considerable academic recognition, with a cumulative citation count of 2,179 as of now. This citation count reflects the profound influence his work has had on the scientific community, particularly in the areas of pharmacogenetics, pharmacometabolomics, and cardiology. His ability to produce impactful, high-quality research is evident through his consistent presence in top-tier journals, where his findings continue to shape the discourse on personalized medicine.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

As Dr. Akkaif continues his postdoctoral work at Fudan University, his future contributions are poised to expand on his research in precision medicine and cardiology. Given his accomplishments thus far, his research promises to lead to more personalized treatment options for cardiovascular diseases, potentially transforming clinical practices and improving patient outcomes globally. His ongoing efforts in understanding the genetic and metabolic factors influencing drug efficacy will likely place him at the forefront of the personalized medicine movement, paving the way for future innovations in the medical field.

🏆KEY AWARDS AND HONORS:

  • Young Researchers Award at the 2022 ESC Asia Conference (Singapore)

  • Second Prize for the Young Investigator Award at the ESC Asia Congress in Singapore 2022

  • Young Ambassador of the European Association of Preventive Cardiology (EAPC) (2022–2024)

  • Reviewing Excellence for over 50 high-impact SCI Q1 and Q2 journals

🌍CONCLUSION:

Dr. Mohammed Ahmed Akkaif’s groundbreaking research in precision medicine and cardiology continues to shape the future of personalized healthcare. With a strong academic background, numerous publications, and recognition through prestigious awards, his work is making significant contributions to improving cardiovascular treatments. His role as a Young Ambassador for the European Association of Preventive Cardiology further highlights his dedication to global health. As he advances his postdoctoral research at Fudan University, Dr. Akkaif’s future endeavors hold the potential to revolutionize clinical practices, particularly in pharmacogenetics and pharmacometabolomics, ensuring more effective and individualized patient care.

TOP NOTABLE PUBLICATIONS:

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in …

Authors: AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, …

Journal: The Lancet

Year: 2024

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease …

Authors: M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, …

Journal: The Lancet

Year: 2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the …

Authors: The Lancet

Year: 2024

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Authors: M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, …

Journal: The Lancet

Year: 2024

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Authors: SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Authors: VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, …

Journal: The Lancet Neurology

Year: 2024

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Authors: NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Authors: MA Akkaif, NAA Daud, A Sha’aban, ML Ng, MAS Abdul Kader, DA Noor

Journal: Molecules

Year: 2021

A review of the effects of ticagrelor on adenosine concentration and its clinical significance

Authors: MA Akkaif, ML Ng, MASA Kader, NAA Daud, A Sha’aban, B Ibrahim

Journal: Pharmacological Reports

Year: 2021

National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050

Authors: M Ng, X Dai, RM Cogen, M Abdelmasseh, A Abdollahi, A Abdullahi, …

Journal: The Lancet

Year: 2024

 

Dong MA | Cardiovascular Researches | Best Researcher Award

Posted on by Pencis

Prof. Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA, Hebei Medical University, China

Prof. Dong Ma is a distinguished professor at Hebei Medical University, China, specializing in medical sciences and healthcare innovations. With a strong academic background, he has made significant contributions to biomedical research, clinical studies, and medical advancements. His work focuses on developing new treatments, improving patient care, and enhancing healthcare methodologies. Prof. Ma’s research is widely cited in prestigious medical journals, influencing global healthcare policies and practices. As a mentor and scholar, he continues to inspire future medical professionals while fostering international research collaborations. His dedication to medical excellence and innovation ensures a lasting impact in the field.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Prof. Dong Ma embarked on his academic journey with a strong foundation in medical sciences. He pursued his education in China, demonstrating exceptional aptitude in the field of medicine and research. His early academic years were marked by rigorous studies, participation in innovative projects, and a keen interest in medical advancements.

🏛️ PROFESSIONAL ENDEAVORS:

Prof. Ma is currently a distinguished professor at Hebei Medical University, China. Throughout his career, he has been actively involved in teaching, mentoring, and guiding students in medical sciences. His professional engagements extend beyond the classroom, contributing to the university’s research and global collaborations in medical research and healthcare advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Prof. Ma’s research primarily revolves around medical sciences, healthcare innovations, and clinical applications. His work includes:

  • Biomedical Research: Investigating novel treatments and technologies in the medical field.
  • Clinical Studies: Conducting evidence-based research to improve patient care and treatment outcomes.
  • Medical Innovations: Developing and contributing to new methodologies and technologies in healthcare.

His dedication to research has significantly impacted both theoretical knowledge and practical medical applications, benefiting healthcare professionals and patients alike.

🌍 IMPACT AND INFLUENCE:

Prof. Ma’s contributions have made a profound impact on the medical community. His research has been cited extensively in academic journals, influencing policies and practices in the field of medicine. His work has also led to collaborations with international medical institutions, further amplifying his influence on global healthcare development.

📖 ACADEMIC CITATIONS:

Prof. Ma has been cited in numerous prestigious medical journals and research papers. His publications cover a wide range of topics, including:

  • Advances in medical treatments and techniques.
  • Healthcare policy improvements.
  • Breakthroughs in disease prevention and management.

His academic work serves as a valuable resource for researchers, scholars, and healthcare professionals worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Dong Ma’s legacy is built upon his relentless pursuit of medical excellence. His future contributions are expected to:

  • Drive Innovation: Further enhance medical technologies and treatment approaches.
  • Inspire Future Scholars: Mentor upcoming medical professionals and researchers.
  • Expand Global Collaborations: Strengthen research ties with international institutions for broader healthcare advancements.

🔥 CONCLUSION:

Prof. Dong Ma stands as a visionary leader in medical sciences, shaping the future of healthcare through groundbreaking research, innovation, and education. His dedication to improving patient care, advancing medical treatments, and mentoring future professionals has left a lasting impact on both academia and clinical practice. With numerous contributions to medical research and extensive collaborations worldwide, he continues to drive progress in healthcare. His legacy is defined by excellence, knowledge, and a passion for medical advancements, ensuring a brighter, healthier future for generations to come.

TOP NOTABLE PUBLICATIONS

The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study

Authors: Xianzhe Lou, Tongguo Miao, Shiya Zhang, Dong Ma, Yuemin Nan

Journal: Chinese General Practice

Year: 2025

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

Authors: Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin Nan

Journal: Scientific Reports

Year: 2024

Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma

Authors: Xizhao Yan, Fenglan An, Zhenzhen Ding, Dong Ma, Xiaohui Yang

Journal: Pakistan Journal of Medical Sciences

Year: 2024

α-HBDH is a superior to LDH in predicting major adverse cardiovascular events in patients with acute aortic dissection

Authors: Yunjing Zhang, Yue Sun, Yongbo Zhao, Dong Ma

Journal: Heliyon

Year: 2024

Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

Authors: Tongguo Miao, Xianzhe Lou, Shiming Dong, Dong Ma, Yuemin Nan

Journal: Journal of Hepatocellular Carcinoma

Year: 2024